Best medication for eczema (atopic dermatitis), honestly
Eczema (atopic dermatitis) isn't just dry skin — it's a combination of a leaky skin barrier and an overactive immune response, which is why the treatments below do two different jobs: repairing the barrier and calming inflammation. They're grouped by their role in treatment, from the moisturiser everyone needs through to the drugs reserved for severe disease, each with what it is, where on the body it fits, our independent recall-safety rating, and the honest safety trade-off — including which carry an FDA boxed warning and which don't.
What actually decides it
Because eczema is both a barrier defect and an immune disease, treatment has two parts that work together: moisturise every day to repair the barrier — for everyone, drug or not — and calm flares with a topical anti-inflammatory. Topical steroids are first-line, but potency has to match the site: a mild steroid like hydrocortisone on the thin skin of the face, eyelids and folds, a stronger one for thick, stubborn skin on hands or feet. Both under-treating out of steroid-phobia and overusing potent steroids on thin skin are real problems. When steroids aren't enough or aren't wanted, the non-steroidal topicals (tacrolimus, pimecrolimus, crisaborole) and, for short courses, topical ruxolitinib step in; disease that topicals can't hold is where the injected biologic dupilumab and the oral JAK inhibitors come in. One honest contrast runs through the newer drugs: every JAK inhibitor — oral (upadacitinib, abrocitinib) and topical (ruxolitinib) — carries an FDA boxed warning for serious infections, blood clots, cardiovascular events and cancer, whereas dupilumab, a biologic, carries none.
Moisturisers (emollients)
Barrier repair — the foundation
Not a drug, and the one step everyone with eczema needs: fragrance-free moisturiser applied liberally and often repairs the leaky skin barrier that drives the disease. Used daily it reduces how often flares happen and how much medicated cream you need. Thicker ointments hold moisture better than lotions; apply within a few minutes of bathing to trap water in the skin. There is no boxed warning and no limit on how much or how long you use it — more is better.
Topical steroids (e.g. hydrocortisone)
Topical corticosteroid
The first-line anti-inflammatory for flares — but potency must match the site. Low-potency hydrocortisone (such as the OTC 1% cream) is the mildest rung and suits thin skin: face, eyelids and skin folds. Thick, lichenified skin on hands, feet or elbows usually needs a mid- or higher-potency prescription topical steroid that a mild cream won't clear; step the strength down as the skin settles. Used in short courses on the right site, topical steroids are effective and carry no FDA boxed warning. The trade-offs are real in both directions: overusing a potent steroid, or using one on thin skin, can thin, bruise or mark the skin, while under-treating out of steroid-phobia leaves the inflammation smouldering.
Tacrolimus ointment (Protopic)
Topical calcineurin inhibitor
A steroid-sparing topical that calms inflammation without thinning the skin, which makes it useful for the face, eyelids and folds and for people who have already used a lot of steroid. It carries an FDA BOXED WARNING: the long-term safety of topical calcineurin inhibitors has not been established, and rare cases of malignancy (skin cancer and lymphoma) have been reported — so continuous long-term use is avoided and application is limited to affected skin. Not indicated in children under 2 years. Expect burning or stinging for the first few days, which usually eases; alcohol can flush the treated skin.
Pimecrolimus cream (Elidel)
Topical calcineurin inhibitor
The milder topical calcineurin inhibitor — a cream for mild-to-moderate eczema that, like tacrolimus, doesn't thin the skin, so it suits the face, eyelids and folds. It carries the same FDA BOXED WARNING: the long-term safety of topical calcineurin inhibitors has not been established, with rare reports of malignancy (skin cancer and lymphoma), so continuous long-term use is avoided and application is limited to affected skin. Not indicated in children under 2 years. Burning or stinging when you first apply it is common and usually settles within a few days.
Crisaborole (Eucrisa)
Topical PDE4 inhibitor
A non-steroidal ointment (a PDE4 inhibitor) for mild-to-moderate eczema that doesn't thin the skin and can be used on the face and in young children. It has no FDA boxed warning. The main drawback is stinging or burning at the site when applied, which for some people is enough to stop it; a rare allergic reaction is possible. A steroid-sparing choice when you want to avoid both steroids and the calcineurin inhibitors' caution against long-term use.
Dupilumab (Dupixent)
Biologic (IL-4/IL-13), injected
The main step up for moderate-to-severe eczema that topicals can't control — an injected biologic that blocks the IL-4/IL-13 immune signals central to the disease. It's given by injection under the skin every two weeks after a starting dose, with the benefit building over about four months, and is usually continued long-term. Notably it has NO FDA boxed warning — the honest contrast with the oral and topical JAK inhibitors, which do. Its characteristic side effects are eye and eyelid inflammation (conjunctivitis) and injection-site reactions; report new eye redness, pain or vision changes to your prescriber.
Ruxolitinib cream (Opzelura)
Topical JAK inhibitor
A topical JAK inhibitor for short-term, non-continuous treatment of mild-to-moderate eczema in people 2 years and older when other topicals haven't controlled it. It works well, but as a JAK inhibitor it carries the class FDA BOXED WARNING (serious infections, death, cancer, major cardiovascular events and blood clots), and the label limits use to match: no more than 20% of the body surface, up to 60 g a week for ages 12 and up (less for younger children), not alongside other JAK inhibitors, biologics or potent immunosuppressants, and not for continuous long-term use. That is why it is a short-course, limited-area option rather than an everyday cream.
How to choose
The honest way to narrow it down — matched to your situation, not a ranking. These are common scenarios, not a complete rulebook; the final choice is a prescriber’s.
- Everyone, every day — the foundation
- A fragrance-free moisturiser (emollient), applied liberally and often, flare or no flare. It's the single step that cuts how often you flare and how much medicated cream you need.
- A flare on the face, eyelids or skin folds (thin skin)
- A low-potency steroid such as hydrocortisone in short bursts, or a steroid-sparing non-steroid (tacrolimus, pimecrolimus or crisaborole), which don't thin skin and are often preferred for these delicate sites.
- A flare on thick skin — hands, feet, elbows
- A mid- or higher-potency prescription topical steroid, which a mild cream won't clear; step the strength down as it settles, then keep moisturising.
- You want to avoid steroids, or have used a lot already
- A non-steroidal topical — a calcineurin inhibitor (tacrolimus/pimecrolimus) or crisaborole — bearing in mind the calcineurin inhibitors' boxed-warning caution against continuous long-term use.
- Mild-to-moderate eczema that keeps breaking through on the same spots
- Short, non-continuous courses of topical ruxolitinib (Opzelura) on a limited area, or 'proactive' twice-weekly steroid or calcineurin inhibitor to the usual hot-spots — a prescriber's plan.
- Moderate-to-severe eczema topicals can't control
- A systemic drug — dupilumab (an injected biologic, no boxed warning) is a common first systemic choice; an oral JAK inhibitor is an alternative but carries the JAK boxed warning.
- Eczema that suddenly turns painful, weepy or crusted
- Have it checked for infection before escalating anti-inflammatory creams — infected eczema, including eczema herpeticum, needs different treatment. These are common scenarios, not a complete rulebook; a clinician tailors the choice.
Eczema (atopic dermatitis) medications at a glance
| Treatment | Type / class | Typical role | FDA boxed warning? | Main watch-out |
|---|---|---|---|---|
| Moisturisers (emollients) | Barrier repair (non-drug) | Foundation for everyone, daily | No | None — apply liberally, flare or not |
| Hydrocortisone (topical steroid) | Corticosteroid, low-potency | First-line for flares; match potency to site | No | Thinning if overused or on thin skin |
| Tacrolimus (Protopic) | Calcineurin inhibitor (TCI) | Steroid-sparing; face, folds | Yes — TCI class | Stinging early; avoid continuous long-term use |
| Pimecrolimus (Elidel) | Calcineurin inhibitor (TCI) | Mild disease; face, folds | Yes — TCI class | Stinging early; avoid continuous long-term use |
| Crisaborole (Eucrisa) | PDE4 inhibitor (topical) | Mild–moderate; steroid-sparing | No | Application-site stinging or burning |
| Ruxolitinib (Opzelura) | JAK inhibitor (topical) | Short-term, up to 20% of body | Yes — JAK class | Limit area and duration; not with immunosuppressants |
| Dupilumab (Dupixent) | Biologic, IL-4/IL-13 (injection) | Moderate–severe disease | No | Eye/eyelid inflammation; injection reactions |
What to expect
Topical steroids and calcineurin inhibitors usually calm a flare within days to about two weeks; you treat until the skin is clear, then stop or step down while keeping up the moisturiser. Crisaborole and topical ruxolitinib work over a few weeks. Dupilumab is injected every two weeks after a starting dose, with the benefit building over about four months, and is generally continued long-term. For skin that keeps flaring in the same spots, a common approach is "proactive" therapy — dabbing a steroid or calcineurin inhibitor onto those hot-spots about twice a week even when clear. Prescribers step potency up or down by response and body site, and reconsider the plan if a correctly used topical hasn't helped after a couple of weeks. The through-line: enough treatment, for long enough, on the right site — then step down to moisturiser.
When to get medical help
- A sudden crop of painful blisters or punched-out sores spreading across eczema, with fever or feeling unwell — this can be eczema herpeticum, a herpes-virus infection that is a medical emergency; do not treat it as an ordinary flare.
- Weeping, yellow-crusted, hot or increasingly painful eczema — signs of a bacterial skin infection, which needs treating before stepping up anti-inflammatory creams.
- Redness covering most of the body with shivering or feeling generally unwell (erythroderma) — seek urgent care.
- On topical steroids: skin that becomes thin, shiny or bruised or develops stretch marks, or a rebound flare when a strong steroid is stopped — signs of overuse; have the potency and duration reviewed.
- On a topical calcineurin inhibitor (tacrolimus or pimecrolimus): a new or enlarging skin lump, a changing mole, or persistently swollen glands — get it checked, given the boxed-warning caution about long-term use, and avoid using it continuously.
- On topical ruxolitinib (Opzelura) or an oral JAK inhibitor: fever or other signs of serious infection, a shingles rash, or chest pain, breathlessness or a swollen, painful leg (possible clot) — these are the JAK boxed-warning risks; seek care.
- On dupilumab (Dupixent): new or worsening eye redness, pain or blurred vision — report it, as eye inflammation is a known effect of this biologic.
- A spreading rash, hives, or swelling of the face, lips or throat with trouble breathing after any product — especially the injected biologic or crisaborole — is a possible allergic reaction; get emergency help.
Frequently asked questions
What is the best treatment for eczema?
There's no single best. The foundation for everyone is a daily fragrance-free moisturiser, plus treating flares with a topical anti-inflammatory — a steroid first-line, with the potency matched to the site (mild on the face and folds, stronger on thick skin). Non-steroidal creams (tacrolimus, pimecrolimus, crisaborole) and short courses of topical ruxolitinib are options, and moderate-to-severe disease steps up to the biologic dupilumab or an oral JAK inhibitor. The right choice depends on severity, body site and your preferences.
Are steroid creams safe for eczema?
Yes, when the potency is matched to the site and they're used in courses — they're first-line and carry no FDA boxed warning. The problems come from the wrong potency or overuse (thinning, bruising and stretch marks, especially on thin skin) or, at the other extreme, from under-using them out of fear so the eczema never settles. Low-potency hydrocortisone suits the face and folds; thicker skin needs a stronger steroid; step down as the skin clears.
What can I use on my face instead of steroids?
The non-steroidal topicals — tacrolimus (Protopic), pimecrolimus (Elidel) and crisaborole (Eucrisa) — don't thin the skin, so they suit the face and eyelids. The two calcineurin inhibitors carry a boxed-warning caution against continuous long-term use, and all three can sting for the first few days. They're a good way to calm delicate sites without steroid-related thinning.
Is Opzelura (ruxolitinib) safe?
It's effective for short-term, limited-area use in mild-to-moderate eczema, but as a JAK inhibitor it carries the class FDA boxed warning — serious infections, blood clots, cardiovascular events and cancer. The label limits it accordingly: short, non-continuous use on no more than 20% of the body, up to 60 g a week, and not alongside other immunosuppressants, biologics or JAK inhibitors. That's why it's a short-course option, not an everyday cream.
Dupixent vs Opzelura — which is safer?
They fill different roles. Opzelura is a topical cream for small areas of mild-to-moderate disease and carries the JAK-class boxed warning. Dupixent (dupilumab) is an injected biologic for moderate-to-severe disease and has no boxed warning; its notable issue is eye and eyelid inflammation. For widespread disease a biologic is often preferred; for a small, stubborn patch a cream makes more sense. A prescriber weighs severity, extent and your health.
Does eczema need antibiotics?
Only if it's infected. Eczema-prone skin is easily colonised and can become infected — weeping, yellow crust, warmth, increasing pain, sometimes fever — and that infection needs treating. Routine antibiotics for non-infected eczema aren't recommended. One warning sign is different: a sudden, painful, blistering flare can be eczema herpeticum, a herpes-virus infection that is a medical emergency and needs antiviral treatment, not antibiotics.
Can eczema be cured?
There's no cure, but it's controllable. Many children improve as they grow up, while adults often have a relapsing-and-remitting course. The realistic goal is control — moisturise daily, treat flares early, and step up to non-steroidal topicals or a systemic drug if needed — rather than a one-time fix. Identifying and avoiding personal triggers (irritants, some allergens) helps stretch out the gaps between flares.
Sources
Treatment-role framing follows standard US clinical guidelines; each drug links to its FDA label and our rating. This is general reference information, not medical advice, and not a recommendation to take any drug — the choice is a decision to make with a clinician. If you are in crisis, call or text 988 (the US Suicide & Crisis Lifeline).